WALTHAM, Mass., June 17 /PRNewswire/ -- ImmuLogic Pharmaceutical
Corporation (Nasdaq: IMUL) announced today that Dr. J. Joseph Marr was
promoted to President and Chief Executive Officer. Dr. Marr joined ImmuLogic
as Executive Vice President for Research in July, 1996, and was promoted to
Executive Vice President for Research and Development in October of that year.
In 1997, Dr. Marr was promoted to President and Chief Operating Officer.
Prior to joining ImmuLogic, he held positions as Vice President for Research
and Development at Ribozyme Pharmaceuticals Inc. and Senior Vice President for
Research at Searle/Monsanto.
ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company,
located in Waltham, MA, focused on the development of reagents for the
diagnosis and treatment of allergies and vaccines for substance abuse. The
Company's press releases are available through Company News On Call by fax at
800-758-5804, ext. 114501, and on the Internet at http://www.prnewswire.com.
SOURCE ImmuLogic Pharmaceutical Corporation
 back to top
Company News On-Call: http://www.prnewswire.com or
fax, 800-758-5804, ext. 114501
CONTACT:
Investor Relations of ImmuLogic
Pharmaceutical Corporation, 781-466-6000
|
